DNB Asset Management AS Increases Holdings in Merck & Co., Inc. $MRK

Posted by on May 16th, 2026

DNB Asset Management AS lifted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 27.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 950,334 shares of the company’s stock after acquiring an additional 201,907 shares during the quarter. DNB Asset Management AS’s holdings in Merck & Co., Inc. were worth $100,032,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. D.A. Davidson & CO. boosted its stake in shares of Merck & Co., Inc. by 4.4% during the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after acquiring an additional 24,576 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 48.9% during the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after acquiring an additional 32,114 shares in the last quarter. Coldstream Capital Management Inc. boosted its stake in shares of Merck & Co., Inc. by 12.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after acquiring an additional 13,940 shares in the last quarter. NEOS Investment Management LLC boosted its stake in shares of Merck & Co., Inc. by 39.9% during the 3rd quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock worth $29,181,000 after acquiring an additional 99,074 shares in the last quarter. Finally, Campbell Capital Management Inc. purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $1,866,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 1.8%

Shares of MRK opened at $111.36 on Friday. The stock has a fifty day moving average of $116.00 and a two-hundred day moving average of $109.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a market capitalization of $275.03 billion, a PE ratio of 31.37, a price-to-earnings-growth ratio of 2.55 and a beta of 0.18. Merck & Co., Inc. has a fifty-two week low of $74.37 and a fifty-two week high of $125.14.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 5.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on MRK shares. Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. Cantor Fitzgerald upped their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Merck & Co., Inc. in a research note on Friday, May 1st. TD Cowen upped their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. Finally, Barclays initiated coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Get Our Latest Stock Report on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.